Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (10012)	1/14/2004 9:09:13 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Welcome Zeta to SI biotech and this thread in particular. Yes indeed, this thread is as good a place as any for individual company questions. You may or may not get a response (there are just too many biotechs for people to cover all of them), but it's fine to ask. In general if it's biotech-related or amusing it is welcome. Only real constraint is no pumping (repeated posts about a single stock with no encouragement from other participants). Technical analysis stuff is also discouraged. I'm afraid I don't follow INGN, so can't help with your question. I see you responded on the Charity thread to the post about dalbavancin in Gram-positive catheter-related bloodstream infections, and that you are a critical-care nurse, so let me ask you something about that study: The primary endpoint showed there was an overall response rate of 87 percent in patients who received once-weekly dalbavancin (20/23)compared to 50 percent in those treated twice daily with vancomycin (14/28). A doctor I know commented that the 50% response rate for vanco seemed unusually low and it was an open-label study. You have any feelings on this? Peter